1 Min Read
April 26 (Reuters) - Ra Pharmaceuticals Inc
* Ra Pharmaceuticals initiates dosing of ra101495 in PNH patients
* Ra Pharmaceuticals Inc says initial data from global phase 2 program expected mid-2017 Source text for Eikon: Further company coverage:
All quotes delayed a minimum of 15 minutes. See here for a complete list of exchanges and delays.
© 2017 Reuters. All Rights Reserved.